SecBot SecBot
SECBOTREPLAY Home › Report › REGN

REGN · Regeneron reported Q2 2026 non-GAAP EPS of $14.29, a 40.1% beat vs…

Regeneron Pharmaceuticals, Inc. · PRESS-RELEASE filed Jul 30, 2026 at 06:30 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Jul 30, 2026 at 06:30 ET

Regeneron reported Q2 2026 non-GAAP EPS of $14.29, a 40.1% beat vs consensus of $10.20, on total revenue of $4.29B (+17% YoY), driven by strong Dupixent (+38%), EYLEA HD (+52%), and Libtayo (+30%) sales. The Sanofi Development Balance was fully repaid, which will boost collaboration profits starting Q3, and the company raised its full-year guidance on gross margins and narrowed R&D and SG&A ranges. The massive EPS beat and raised fundamentals support a bullish read, though GAAP net income declined 7% due to a $127M IPR&D charge and higher tax rate.

  • Q2 2026 total revenue $4.29B (+17% YoY), above $3.83B consensus
  • Non-GAAP EPS $14.29 vs consensus $10.20 (+40.1% beat)
  • GAAP EPS $12.23 (includes $1.02 negative IPR&D impact)
  • Dupixent global net sales +38% to $6.0B; EYLEA HD U.S. +52% to $596M; Libtayo global +30% to $489M

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access